Grown Rogue International (GRUSF) Non-Current Deffered Revenue (2017 - 2021)
Grown Rogue International's (GRUSF) quarterly Non-Current Deffered Revenue came in at -$8347.3 in Q4 2021, down 179.54% year-on-year from $10494.0 in Q4 2020, and down 179.54% quarter-over-quarter from $10494.0 in Q4 2020.
Grown Rogue International (GRUSF) Non-Current Deffered Revenue (2017 - 2021) Analysis & Trends
Grown Rogue International's Non-Current Deffered Revenue history runs 5 years deep, the most recent figure standing at -$8347.3 for Q4 2021.
- On a quarterly basis, Non-Current Deffered Revenue fell 179.54% year-over-year to -$8347.3 in Q4 2021; TTM through Oct 2021 was -$8347.3, a 179.54% decrease from a year earlier, with the FY2021 full-year figure at -$8345.4, down 179.53% from the prior year.
- Non-Current Deffered Revenue declined to -$8347.3 in Q4 2021 per GRUSF's latest filing, from $10494.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $36881.0 in Q2 2018 and bottomed at -$8347.3 in Q4 2021.
- The 5-year median for Non-Current Deffered Revenue is $26475.0 (2019), against an average of $23701.9.
- Across the five-year window, Non-Current Deffered Revenue advanced 25.47% in 2018 and sank 179.54% in 2021, its largest moves.
- Year by year, Non-Current Deffered Revenue stood at $24912.0 in 2017, then gained by 25.47% to $31256.0 in 2018, then decreased by 21.6% to $24505.0 in 2019, then tumbled by 57.18% to $10494.0 in 2020, then sank by 179.54% to -$8347.3 in 2021.
- Per Business Quant, the three latest GRUSF Non-Current Deffered Revenue figures stand at -$8347.3 (Q4 2021), $10494.0 (Q4 2020), and $19690.0 (Q3 2020).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Grown Rogue International | 99.97 Mn | 92.67 Mn | 3.96 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Oct 31, 2021 | -8,347.32 |
| Oct 31, 2020 | 10,494.00 |
| Jul 31, 2020 | 19,690.00 |
| Apr 30, 2020 | 29,400.00 |
| Jan 31, 2020 | 34,238.00 |
| Oct 31, 2019 | 24,505.00 |
| Jul 31, 2019 | 25,819.00 |
| Apr 30, 2019 | 27,131.00 |
| Jan 31, 2019 | 28,444.00 |
| Oct 31, 2018 | 31,256.00 |
| Apr 30, 2018 | 36,881.00 |
| Oct 31, 2017 | 24,912.00 |